Dramatic fate of a young coronary heart disease patient rescued with specific lipoprotein(a) apheresis. J Clin Apher 2015 Jun;30(3):193-5
Date
09/03/2014Pubmed ID
25181645DOI
10.1002/jca.21356Scopus ID
2-s2.0-84930854418 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Lipoprotein(a) [Lp(a)] is acknowledged to be an independent atherothrombotic risk factor. Although genetic studies have highlighted the causal relationship between coronary disease and Lp(a), it is uncertain which strategies maximize the therapeutic benefit of patients with high Lp(a) levels. We report the challenging case of a young coronary heart disease (CHD) patient who underwent 10 percutaneous coronary interventions due to repeated acute coronary syndromes (2006-2009) despite an optimally controlled, traditional risk-factor profile. For the first time, we performed specific Lp(a) immunoadsorption in the presence of very low levels of low-density lipoprotein cholesterol (LDL-C) while the patient was on a high-dose statin regimen. There have been no previous reports of patients with high Lp(a) levels who achieved LDL-C goals when treated with an isolated Lp(a)-lowering method. Despite the very high risk of cardiovascular death, targeting Lp(a) resulted in dramatic improvement of the patient's clinical condition. Thus, we suggest that specific Lp(a) apheresis should be considered an effective new treatment strategy for patients with progressive CHD who have reached LDL-C goals but harbor elevated Lp(a) levels.
Author List
Safarova MS, Ezhov MV, Afanasieva OI, Konovalov GA, Pokrovsky SNAuthor
Maya Safarova MD, PhD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultBlood Component Removal
Cholesterol, LDL
Coronary Disease
Disease Progression
Humans
Lipoprotein(a)
Male
Risk Factors
Treatment Outcome









